ArticleCureus2025
Indian Clinicians' Perspectives on Utilizing Dapagliflozin-Based Combination Therapy for the Management of Obesity in Patients With Type 2 Diabetes Mellitus.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundIn India, abdominal obesity is highly prevalent among both men and women and is associated with an increased risk of developing type 2 diabetes mellitus (T2DM). This presents a dual challenge for Indian clinicians in simultaneously managing body weight and glycemic levels. This article aimed to understand Indian clinicians' perspectives regarding obesity and T2DM association and utilization of dapagliflozin+metformin combination therapy for obesity management in patients with T2DM.
methodsA cross-sectional online survey was conducted with 914 Indian clinicians, including endocrinologists, diabetologists, consultants, and general physicians. A structured questionnaire was used to evaluate clinicians' knowledge of the role of obesity in T2DM, their attitudes toward weight management, and current practices in addressing obesity in patients with T2DM. The survey also assessed clinicians' utilization of pharmacological and nonpharmacological interventions, and their perceptions of barriers to effective obesity management. Data from the questionnaires were analyzed using Statistical Package for the Social Sciences version 29.0 (IBM Corp., Armonk, NY). Descriptive and inferential statistics were also calculated. Statistical significance was set at p< 0.05.
resultsOf the 914 clinicians, 910 (99.50%) agreed that weight management and glycemic control in T2DM patients are the primary treatment goals. Cardiovascular disease and hypertension were identified as the most recognized complications of obesity in T2DM patients by 742 (81.80%) and 682 (74.61%) clinicians, respectively. Dapagliflozin+metformin fixed-dose combinations (FDCs) were the preferred initial glucose-lowering combination for overweight/obese T2DM patients by 624 (68.28%) clinicians, followed by dapagliflozin+sitagliptin FDCs by 390 (42.68%) clinicians. Glycemic control, weight loss, and cardiovascular and renal benefits are critical considerations for clinicians. A majority of 670 (73.30%) clinicians reported noncompliance, followed by 570 (62.36%) who reported pill burden as a significant barrier to managing obesity in patients with T2DM.
conclusionMost Indian clinicians recognize the importance of obesity management in patients with T2DM. However, patient noncompliance and pill burden were identified as significant barriers to managing obesity in these patients. There is a preference for dapagliflozin+metformin FDCs in the management of overweight T2DM patients. Thus, prescribing FDCs in routine clinical practice and ensuring patient access could improve the outcomes in this high-risk group.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.